SI-BONE, Inc. Common Stock
SIBNSI-BONE, Inc. is a medical device company specializing in minimally invasive solutions for the treatment of musculoskeletal disorders of the sinonasal and sacroiliac joint regions. The company develops and commercializes products designed to improve patient outcomes by addressing conditions related to the pelvis and sacroiliac joint, with a focus on innovative, image-guided procedures.
Company News
SI-BONE announced preliminary Q4 2025 revenue of $56.2-$56.3 million (~15% growth) and full year 2025 revenue of $200.8-$200.9 million (~20% growth). The company reported ~1,640 active U.S. physicians (18% increase) and cash equivalents of ~$147.7 million with net cash generation of ~$2.0 million in Q4. Final audited results will be provided in l...
SI-Bone reported strong Q3 results with 21% revenue growth, narrowed net losses, and increased physician adoption, leading to a significant stock price surge.
SI-Bone reported a data breach on October 1, 2025, potentially exposing sensitive personal information including names, Social Security numbers, and medical details. A law firm is investigating potential legal action on behalf of affected customers.
Four under-the-radar companies - Porch Group, SunOpta, Tutor Perini, and Si-Bone - reported strong earnings in Q1 2025 and are seeing positive momentum in May.
Inogen is well-positioned for growth in the portable oxygen concentrator (POC) market, with a strong product portfolio and solid Q2 results. However, it faces stiff competition and forex volatility. The company's stock has outperformed the industry and the S&P 500 year-to-date.
